Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Nov 7

PMID 25375122

Citations 19

Authors

Satoko Yamaguchi

Yoshiko Maida

Mami Yasukawa

Tomoyasu Kato

Masayuki Yoshida

Kenkichi Masutomi

Affiliations

Soon will be listed here.

Abstract

Treatment of advanced ovarian cancer involves platinum-based chemotherapy. However, chemoresistance is a major obstacle. Cancer stem cells (CSCs) are thought to be one of the causes of chemoresistance, but the underlying mechanism remains elusive. Recently, human telomerase reverse transcriptase (hTERT) has been reported to promote CSC-like traits. In this study, we found that a mitotic inhibitor, eribulin mesylate (eribulin), effectively inhibited growth of platinum-resistant ovarian cancer cell lines. Eribulin-sensitive cells showed a higher efficiency for sphere formation, suggesting that these cells possess an enhanced CSC-like phenotype. Moreover, these cells expressed a higher level of hTERT, and suppression of hTERT expression by siRNA resulted in decreased sensitivity to eribulin, suggesting that hTERT may be a target for eribulin. Indeed, we found that eribulin directly inhibited RNA-dependent RNA polymerase (RdRP) activity, but not telomerase activity of hTERT in vitro. We propose that eribulin targets the RdRP activity of hTERT and may be an effective therapeutic option for CSCs. Furthermore, hTERT may be a useful biomarker to predict clinical responses to eribulin.

Citing Articles

Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.

Mochizuki T, Ikegami M, Akiyama T Cancer Sci. 2023; 115(2):575-588.

PMID: 38115234 PMC: 10859616. DOI: 10.1111/cas.16050.

Suppression of alpha-tubulin acetylation potentiates therapeutic efficacy of Eribulin in liver cancer.

Zhong Y, Wang C, Wang Y, Wu Y, Wang H, Qiu S Am J Cancer Res. 2023; 13(11):5698-5718.

PMID: 38058833 PMC: 10695797.

Eribulin is an immune potentiator in breast cancer that upregulates human leukocyte antigen class I expression via the induction of NOD-like receptor family CARD domain-containing 5.

Wada A, Hirohashi Y, Kutomi G, Murata K, Iwabuchi S, Mizue Y Cancer Sci. 2023; 114(12):4511-4520.

PMID: 37991442 PMC: 10728009. DOI: 10.1111/cas.15986.

Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs.

Matsuda Y, Yamashita T, Ye J, Yasukawa M, Yamakawa K, Mukai Y J Pathol. 2022; 257(2):172-185.

PMID: 35094384 PMC: 9315154. DOI: 10.1002/path.5876.

Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma.

Nakano T, Fujimoto K, Tomiyama A, Takahashi M, Achiha T, Arita H Cancer Sci. 2021; 113(2):697-708.

PMID: 34839570 PMC: 8819309. DOI: 10.1111/cas.15221.

References

Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N . An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature. 2009; 461(7261):230-5. PMC: 2755635. DOI: 10.1038/nature08283. View

Choi J, Southworth L, Sarin K, Venteicher A, Ma W, Chang W . TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet. 2008; 4(1):e10. PMC: 2211538. DOI: 10.1371/journal.pgen.0040010. View

Smith J, Wilson L, Azarenko O, Zhu X, Lewis B, Littlefield B . Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2009; 49(6):1331-7. PMC: 2846717. DOI: 10.1021/bi901810u. View

Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

Lin T, Meng L, Li Y, Tsai R . Tumor-initiating function of nucleostemin-enriched mammary tumor cells. Cancer Res. 2010; 70(22):9444-52. PMC: 2982898. DOI: 10.1158/0008-5472.CAN-10-2159. View

Towle M, Salvato K, Wels B, Aalfs K, Zheng W, Seletsky B . Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2010; 71(2):496-505. DOI: 10.1158/0008-5472.CAN-10-1874. View

Cortes J, OShaughnessy J, Loesch D, Blum J, Vahdat L, Petrakova K . Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377(9769):914-23. DOI: 10.1016/S0140-6736(11)60070-6. View

Wang J, Zhou J, Wu G . Bim protein degradation contributes to cisplatin resistance. J Biol Chem. 2011; 286(25):22384-92. PMC: 3121386. DOI: 10.1074/jbc.M111.239566. View

Okamoto N, Yasukawa M, Nguyen C, Kasim V, Maida Y, Possemato R . Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A. 2011; 108(51):20388-93. PMC: 3251068. DOI: 10.1073/pnas.1015171108. View

10.

Dong C, Li Z, Alvarez Jr R, Feng X, Goldschmidt-Clermont P . Microtubule binding to Smads may regulate TGF beta activity. Mol Cell. 2000; 5(1):27-34. DOI: 10.1016/s1097-2765(00)80400-1. View

11.

Provencher D, Lounis H, Champoux L, Tetrault M, Manderson E, Wang J . Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim. 2000; 36(6):357-61. DOI: 10.1290/1071-2690(2000)036<0357:COFNEO>2.0.CO;2. View

12.

Ohta I, Gorai I, Miyamoto Y, Yang J, Zheng J, Kawata N . Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells. Cancer Lett. 2000; 162(1):39-48. DOI: 10.1016/s0304-3835(00)00605-4. View

13.

Takano M, Tsuda H, Sugiyama T . Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?. J Exp Clin Cancer Res. 2012; 31:53. PMC: 3405444. DOI: 10.1186/1756-9966-31-53. View

14.

Horn S, Figl A, Rachakonda P, Fischer C, Sucker A, Gast A . TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339(6122):959-61. DOI: 10.1126/science.1230062. View

15.

Huang F, Hodis E, Xu M, Kryukov G, Chin L, Garraway L . Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339(6122):957-9. PMC: 4423787. DOI: 10.1126/science.1229259. View

16.

Medema J . Cancer stem cells: the challenges ahead. Nat Cell Biol. 2013; 15(4):338-44. DOI: 10.1038/ncb2717. View

17.

Killela P, Reitman Z, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr L . TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110(15):6021-6. PMC: 3625331. DOI: 10.1073/pnas.1303607110. View

18.

Liu Z, Li Q, Li K, Chen L, Li W, Hou M . Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 2012; 32(36):4203-13. DOI: 10.1038/onc.2012.441. View

19.

Chung S, Aroh C, Vadgama J . Constitutive activation of STAT3 signaling regulates hTERT and promotes stem cell-like traits in human breast cancer cells. PLoS One. 2014; 8(12):e83971. PMC: 3875492. DOI: 10.1371/journal.pone.0083971. View

20.

Wu R, Ayhan A, Maeda D, Kim K, Clarke B, Shaw P . Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol. 2013; 232(4):473-81. PMC: 3946218. DOI: 10.1002/path.4315. View